SEATTLE & BALTIMORE--(BUSINESS WIRE)--June 1, 2006--Targeted Genetics Corporation (Nasdaq:TGEND - News) will present interim data from its ongoing Phase I/II trial of tgAAC94 in patients with inflammatory arthritis today at the American Society of Gene Therapy (ASGT) 2006 Annual Meeting. Pervin Anklesaria, Ph.D., Vice President, Therapeutic Development at Targeted Genetics, will present highlights of initial data from the ongoing Phase I/II and a summary of the recently completed Phase I clinical trials of tgAAC94. The data will be presented in an oral presentation, titled “Clinical Development of an AAV Vector Expressing the TNF Receptor: Fc Fusion Gene in Inflammatory Arthritis,” as part of a workshop on musculoskeletal gene expression and Immunology of musculoskeletal gene therapy. The Company will hold a conference call with investors and analysts at 4:30 PM Eastern Time today. The call will be broadcast live and can be accessed, along with replay information, at www.targetedgenetics.com.
